Sira Nanthapisal

Thammasat University — Thailand

Medicine · Health Sciences

16h-index932citations78works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(20), Allergic Rhinitis and Sensitization(13), Asthma and respiratory diseases(11), COVID-19 Clinical Research Studies(10), Inflammasome and immune disorders(6)

Publications77 total

Specific IgE to tropomyosin increases the diagnostic accuracy of shrimp allergy
Frontiers in Allergy·2026Open Access
Evaluation of a gravity-driven automated nasal irrigation system compared with manual syringe irrigation: a randomized crossover trial
International Journal of Otorhinolaryngology and Head and Neck Surgery·2026Open Access
The comparison of Immune response to Third booster dose with of ChAdOx-1 or BNT162b2 COVID-19 vaccine in healthcare workers after receiving two doses of CoronaVac
Mendeley Data·2026Open Access
The comparison of Immune response to Third booster dose with of ChAdOx-1 or BNT162b2 COVID-19 vaccine in healthcare workers after receiving two doses of CoronaVac
Mendeley Data·2026Open Access
Immune responses after two inactivated COVID-19 vaccine doses, a heterologous third dose and subsequent boosting with bivalent mRNA in adults
Scientific Reports·2025Open Access
Screening Tool to Predict Allergy Test Results in Children with Rhinitis
2025Open Access
Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S)
Vaccine·2025Open Access
Real-world immune response to SARS-CoV-2 vaccination in Thai patients with systemic lupus erythematosus: a cross-sectional observational study
Lupus Science & Medicine·2025Open Access
The feasibility of procalcitonin and CPIS score to reduce inappropriate antibiotics use among severe-critically ill COVID-19 pneumonia patients: A pilot study
UNC Libraries·2025Open Access
Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines
Vaccines·2025Open Access
The role of gut microbiota in obesity severity and metabolic risk in pediatric populations
Nutrition Metabolism and Cardiovascular Diseases·2025· 4 cited
Immune response of bivalent mRNA booster in adults who had received a primary series of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike (NDV-HXP -S)
International Journal of Infectious Diseases·2025Open Access
Boosting effects of additional mRNA COVID-19 vaccine given after one year in adults previously received two doses inactivated COVID-19 vaccines with third dose of any COVID-19 vaccine during Omicron XBB.1.5
International Journal of Infectious Diseases·2025Open Access
Allergic rhinitis and urticaria burden and antihistamine treatment options in Thailand: A modified Delphi study
Journal of Allergy and Clinical Immunology Global·2025Open Access
Clean Air for Asthma and Allergy Programme (CAAP), a randomized controlled trial to evaluate the effectiveness of multicomponent interventions to reduce indoor triggers in childhood asthma
Asia Pacific Allergy·2025Open Access
Immune Responses to a Heterologous Booster with Mrna Based Covid-19 Vaccine after Priming with an Inactivated Newcastle Disease Virus Recombinant Vaccine Expressing the Sars-Cov-2 Spike Protein (Ndv-Hxp-S)
SSRN Electronic Journal·2025Open Access
Immune Responses of Adults Previously Received Two Doses of Inactivated Covid-19 Vaccines, and Third Dose of Any Covid-19 Vaccine Boosted with Bivalent Mrna Ancestral/Omicron Ba.4/5 Vaccine
SSRN Electronic Journal·2025Open Access
The comparison of Immune response to Third booster dose with of ChAdOx-1 or BNT162b2 COVID-19 vaccine in healthcare workers after receiving two doses of CoronaVac
2024Open Access
Promoting patient-centred care in the management of allergic rhinitis in Asia-Pacific countries
World Allergy Organization Journal·2024· 3 citedOpen Access
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial
Vaccine·2024· 5 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Paul Brogan(16), Despina Eleftheriou(14), Ebun Omoyinmi(12), Nigel Klein(12), Prapasri Kulalert(10), Ariane Standing(9), Kimberly Gilmour(8), Paskorn Sritipsukho(7), Orapan Poachanukoon(7), Anan Jongkaewwattana(7), Ying Hong(6), Punnee Pitisuttithum(6), Claire Murphy(5), Auchara Tangsathapornpong(5), Pornumpa Bunjoungmanee(5), Nattiya Hirankarn(5), Arunee Thitithanyanont(5), Sant Muangnoicharoen(5), Viravarn Luvira(5), Sónia Gomes(4)